Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRebecca Wurm‐KuczeraCAChidimma Agatha AkpaETEugen Tausch

Discussion

Loading...

Member takes

Overview

Phase II trial shows clinical data and biomarkers linked to progression-free survival in Richter transformation patients, suggesting treatment efficacy of PD-1 and BTK inhibitors.

Key Points

  • To evaluate the effectiveness of combined checkpoint and BTK inhibition in Richter transformation patients and identify associated biomarkers.
  • Phase II trial with patients having histologically confirmed Richter transformation
  • Treatment with tislelizumab and zanubrutinib
  • Endpoints included overall response rate, progression-free survival, and biomarker analysis through sequencing.
  • Overall response rate of 58.3%, with 14.5% achieving complete response
  • Median progression-free survival of 10.0 months
  • Biomarkers like gene expression and somatic mutations correlated with clinical outcomes.

Cite This Study

Wurm‐Kuczera et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d000https://doi.org/10.1182/blood-2025-90
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial2025
  2. 2Pre-existing cytotoxic capacity of CD8+ and CD4+ T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy2025
  3. 3A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation2025
  4. 4Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).2025
  5. 5Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.2025